WHO ICTRP trial
A phase II study of palbociclib for recurrent or refractory advanced thymic…
KCT0003820 · Clinical Research Information Service (CRIS) · Recruiting
Key facts
| Trial ID | KCT0003820 |
|---|---|
| Public title | A phase II study of palbociclib for recurrent or refractory advanced thymic epithelial tumor(TET) |
| Scientific title | A phase II study of palbociclib for recurrent or refractory advanced thymic epithelial tumor |
| Primary sponsor | Samsung Medical Center |
| Registry | Clinical Research Information Service (CRIS) |
| Recruitment status | Recruiting |
| Study type | Interventional Study |
| Phase | Phase2 |
| Countries | Korea, Republic of |
| Conditions | Neoplasms |
| Interventions | Drug : Patients will receive oral palbociclib 125mg daily for 21days followed by a 7-day break. Cycle will be repeated every 28 days. Patients will continue to receive Palbociclib until objective disease progression, symptomatic… |
| Registration date | Apr 19, 2019 |
| Target size | 33 |
| Secondary IDs | NCT03219554 |
| Registry page | cris.nih.go.kr |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: